Core outcome set for diabetes after pregnancy prevention across the life span: international Delphi study by Wu, N et al.
BMJ Open Diab Res Care 2020;8:e001594. doi:10.1136/bmjdrc-2020-001594
Open access 
1
Core outcome set for diabetes after 
pregnancy prevention across the life 
span: international Delphi study
Nancy Wu,1 Sharleen O'Reilly,2 Karoline Kragelund Nielsen,3 
Helle Terkildsen Maindal,3,4 Kaberi Dasgupta   1,5
For numbered affiliations see 
end of article.
Correspondence to
Dr Kaberi Dasgupta;  
 kaberi. dasgupta@ mcgill. ca
To cite: Wu N, O'Reilly S, 
Nielsen KK, et al. Core outcome 
set for diabetes after pregnancy 
prevention across the life span: 
international Delphi study. 
BMJ Open Diab Res Care 
2020;8:e001594. doi:10.1136/
bmjdrc-2020-001594
 ► Supplemental material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjdrc- 2020- 001594).
Received 20 May 2020
Revised 10 September 2020
Accepted 28 September 2020
Original research
Epidemiology/Health services research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Introduction Mothers with gestational diabetes mellitus 
(GDM) are at high risk of future diabetes. An active area 
of research examines health behavior change strategies 
in women within 5 years of a GDM pregnancy to prevent 
diabetes after pregnancy. We aimed to develop a core 
outcome set (COS) to facilitate synthesis and comparison 
across trials.
Research design and methods Candidate outcomes 
were identified through systematic review and scored for 
importance (1–9) by healthcare professionals, researchers, 
and women with prior GDM through an international 
two- round electronic- Delphi survey. Outcomes retained 
required round two scores above prespecified thresholds 
(≥70% scoring 7–9) or expert panel endorsement when 
scores were indeterminate. The panel organized the COS 
by domain.
Results 115 stakeholders participated in the survey and 
56 completed both rounds. SD of scores decreased by 0.24 
(95%CI 0.21 to 0.27) by round 2, signaling convergence. 
The final COS includes 19 domains (50 outcomes): 
diabetes (n=3 outcomes), other related diseases (n=3), 
complications in subsequent pregnancy (n=2), offspring 
outcomes (n=3), adiposity (n=4), cardiometabolic 
measures (n=5), glycemia (n=3), physical activity (n=2), 
diet (n=4), breast feeding (n=2), behavior change theory 
(n=5), diabetes- related knowledge (n=2), health literacy 
(n=1), social support (n=1), sleep (n=1), quality of life 
(n=1), program delivery (n=4), health economic evaluation 
(n=2), and diabetes risk screening (n=2). The seven 
outcomes endorsed by ≥90% were diabetes development 
and GDM recurrence, attending the postpartum diabetes 
screening and completing oral glucose tolerance testing 
and/or other glycemia measures, weight and total energy 
intake, and health behaviors in general. Among the 15 at 
the 80%–90% endorsement level, approximately half were 
specific elements related to the top 7, while the remainder 
related to diabetes knowledge, personal risk perception, 
motivation for change, program element completion, and 
health service use and cost.
Conclusion Researchers should collect and report 
outcomes from the breadth of domains in the COS.
INTRODUCTION
Gestational diabetes mellitus (GDM) is a 
critical public health issue, having both a 
high incidence and demonstrated associa-
tions with diabetes after pregnancy (DAP) in 
mothers, offspring, and even fathers.1 2 The 
US Diabetes Prevention Program trial proved 
that DAP in mothers is preventable through 
health behavior change in women whose 
pregnancy averaged a decade before enroll-
ment.3 However, most incident diabetes cases 
occur within 5 years of GDM.4 We aimed to 
identify a core outcome set (COS) for the 
increasing number of trials testing health 
behavior change interventions for DAP 
prevention sooner after pregnancy.
A COS represents the standard set of 
outcomes to measure for a given population, 
in a particular field of interest. It facilitates 
comparison and synthesis, and allows for 
iterative advancement. In October 2017, we 
launched the international Core Outcome 
Set for Diabetes after Pregnancy Prevention 
Trials (COS- DAP) initiative. Our focus was 
the development and testing of interventions 
Significance of this study
What is already known about this subject?
 ► Health behavior change can reduce diabetes inci-
dence in women who are at high risk reflected by 
a history of gestational diabetes mellitus (GDM). 
An increasing number of trials are testing inter-
ventions soon after pregnancy to accomplish this. 
Researchers are measuring a variety of different 
outcomes.
What are the new findings?
 ► Healthcare providers, researchers, and women with 
GDM specified a core outcome set (COS) that moves 
beyond biological measures to include behavioral, 
contextual, process, and economic measures.
How might these results change the focus of 
research or clinical practice?
 ► By addressing the domains highlighted by this COS, 
strategies can be refined iteratively to achieve ap-
proaches that are both effective and feasible to 
translate into programs and practice for diabetes 
prevention.
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that are efficacious for DAP prevention, compatible with 
the needs of women with young families, and feasible to 
be translated into programs. In accordance with Core 
Outcome Measures in Effectiveness Trials (COMET) 
guidelines, we registered and published both our COS 
development protocol and the systematic review from 
which we derived candidate outcomes.5–7 We herein 
report the findings from our two- round electronic 
(e)- Delphi survey among a large international stake-
holder group representing healthcare professionals 
(HCPs), researchers, and women with prior GDM; and 
the final COS.
COS development is a relatively new field and, as such, 
is subject to methodological debate. Concurrent with our 
initiative, another group developed a COS with a similar 
target population but a more general scope of evaluating 
metrics to monitor following a GDM pregnancy; subse-
quent to their e- Delphi survey, they removed a large 
number of highly endorsed outcomes at a consensus 
panel meeting in the interest of brevity, retaining indi-
cators of glycemia, blood pressure, and breastfeeding 
status.8 In contrast, we applied a priori scoring criteria 
for inclusion based on e- Delphi results, with only inde-
terminate outcomes voted on by a consensus panel. 
We thus present a COS that maintains fidelity with the 
e- Delphi survey, capturing biological, behavioral, contex-
tual, process, and economic measures. Its comprehensive 
scope may not only permit the detection of biological 
impact but also facilitate progress toward the ultimate 
goal of translating findings into real- world programs.
METHODS
We registered COS- DAP with the COMET initiative.
Identification of candidate outcomes
As previously reported, we conducted a systematic review 
focused on health behavior change (ie, eating and phys-
ical activity) and diabetes screening intervention studies 
in women with previous GDM.7 Briefly, two investiga-
tors independently screened titles and abstracts, and at 
least three reviewed the full text of selected articles and 
extracted candidate outcomes verbatim. A face- to- face 
meeting among investigators was held in Dublin, Ireland 
(March 2018), for deduplication, suggestion of poten-
tially important outcomes not identified in the review, 
and outcome grouping, in preparation for the e- Delphi 
survey.
Participants
Researchers and HCPs are knowledgeable in GDM 
management, risks, and DAP prevention interventions. 
Women with GDM can speak to the nuances of living 
with GDM and the experience of outcome assessments, 
particularly if they have participated in DAP prevention 
intervention studies. We recruited from all three of these 
stakeholder groups. As recommended for Delphi studies,9 
we aimed for 20–50 respondents per group. Email invita-
tions and social media posts were disseminated through 
pregnancy and diabetes organizations at international 
(eg, International Federation of Gynecology and Obstet-
rics), national (eg, Diabetes Canada and Diabetes 
Ireland), and regional levels (eg, motherhood groups). 
HCPs and researchers were asked to invite patients 
enrolled in previous GDM studies. Interested individuals 
were provided with a link to the survey website.
Survey
The survey was hosted on the online COMET Delphi-
Manager system10 in English, French, and Danish. Round 
1 was open from July to September 2018, and round 2 
was open from October to December 2018. Registration 
and consent were completed electronically; general char-
acteristics were queried. Participants rated each outcome 
on an ordinal scale (1=unimportant to 9=very important) 
or indicated inability to score. We provided a plain 
language definition for each outcome. During round 
1, respondents could suggest additional outcomes. All 
who initiated round 1 were invited to complete a second 
round. During round 2, participants were asked to rerate 
all outcomes after considering their initial ratings and 
average ratings from each stakeholder group, which 
were displayed for each outcome. We held an investi-
gator meeting after round 1 in Halifax, Canada (October 
2018), alongside the 2018 Diabetes Canada Conference 
to plan the consensus meeting.
Analysis
Adopting an approach described by other COS devel-
opers and COMET,11 12 we retained outcomes for which 
≥70% of participants scored 7–9 and ≤15% scored 1–3. 
We excluded outcomes that ≥70% of participants scored 
1–3 and ≤15% scored 7–9. All others were considered 
indeterminate and brought forward to the consensus 
meeting. We analyzed the change in SD of each outcome’s 
scores from round 1 to 2, one of the approaches to quan-
tify convergence described by the COMET initiative.11 All 
analyses were performed in R V.3.5.1.
Consensus meeting
The meeting was a satellite event of the 10th Interna-
tional Symposium on Diabetes, Hypertension, Metabolic 
Syndrome, and Pregnancy held in Florence, Italy (May 
2019). The 15 voting consensus panel members repre-
sented eight countries (Australia, Canada, Denmark, 
Hong Kong (China), Ireland, Israel, Norway, and Switzer-
land) with experts in medicine (eg, obstetrics, endocri-
nology, and internal medicine), nutrition, public health, 
and epidemiology. All but one had not participated in 
the e- Delphi survey. Patient representatives were absent.
The meeting followed a modified nominal group 
format. Panel members discussed each indeterminate 
outcome, then voted anonymously via FormPlus13 to 
accept, reject, or indicate uncertainty on its inclusion 
in the COS. An indeterminate outcome was retained 
if ≥70% of members voted in favor. Panel members 
also discussed how to group outcomes into domains 
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and when to measure them. Suggestions for additional 
outcomes were discussed over email and voted for inclu-
sion with the same criteria, through the online platform 
SurveyMonkey.14
RESULTS
The systematic review identified 172 outcomes.7 Collapse 
of overlapping constructs yielded the 121 included in 
the e- Delphi survey. Round 2 included an additional 33 
outcomes suggested by participants during round 1.
One hundred thirty- four individuals from 23 countries 
registered for the e- Delphi survey. Round 1 was initiated 
by 115 stakeholders (HCP n=54, researcher n=27, women 
with prior GDM n=34). Across stakeholder groups, most 
were women >30 years of age and of European ethnicity 
(table 1). Women with a GDM history were a median 
of 4 years past their last GDM pregnancy. Over half of 
them had ≥2 pregnancies, and 12% had developed type 
2 diabetes in the years following the GDM pregnancy. Of 
the HCPs, 35% were obstetricians/gynecologists; 26% 
were dietitians; and 19% were endocrinologists. Over 50% 
of HCPs spent the majority of time on clinical activities. 
Among the researchers, 60% dedicated the majority of 
their time to research activities; some reported a clinical 
background in obstetrics/gynecology (15%), dietetics 
(11%), endocrinology (11%), and nursing (3.7%). Sixty- 
seven people initiated round 2, and 56 completed both 
rounds in entirety (49% of survey initiators).
The median SD of scores in round 1 was 1.84 (IQR 
1.62–2.17) and that in round 2 was 1.61 (IQR 1.33–1.91). 
Table 1 Characteristics of survey initiators by stakeholder and survey round* (% of n)
Characteristic
HCP Researcher Patient
n=54 n=34 n=27 n=21 n=34 n=12
Women 75.9 73.5 77.8 76.2 100 100
Age (years)
  <30 5.6 5.8 11.1 9.5 5.9 8.3
  30–50 46.3 41.1 37 71.4 58.8 83.3
  >50 48.1 52.9 51.8 19 35.3 8.3
Ethnicity
  European 61.1 61.8 63 61.9 61.8 58.3
  East Asian 5.6 5.9 3.7 4.8 8.8 16.7
  Latin American 1.9 0 7.4 9.5 5.9 8.3
  Other† 29.5 26.4 25.9 23.8 23.5 16.7
  No answer 1.9 5.9 0 0 0 0
Country
  Denmark 14.8 17.6 14.8 19 14.7 0
  Canada‡ 16.7 14.7 0 0 58.8 75
  Australia 22.2 23.5 29.6 33.3 2.9 0
  Ireland 9.3 8.8 11.1 9.5 17.6 16.7
  Other§ 37 35.4 44.5 38.2 6 8.3
Type of HCP
  Obstetrician/gynecologist 35.2 35.3 14.8 9.5
  Dietitian 25.9 23.5 11.1 9.5
  Endocrinologist 18.5 23.5 11.1 9.5
  Nurse 5.6 2.9 3.7 4.8
  Internist 1.9 2.9 0 0
  Other¶ 7.3 3.1 18.5 9.5
  No answer 5.6 8.8 40.7 57.1
*Left and right columns within each stakeholder group represent n in the first and second rounds of the survey, respectively. Participants who 
identified as researchers were not explicitly queried for a healthcare profession background.
†Indigenous, African origin, South Asian, Southeast Asian, West Asian, or a combination of ethnicities.
‡HCPs from Canada with research activity chose not to identify as researchers.
§Argentina, Austria, Brazil, Croatia, Estonia, Germany, Hong Kong, India, Iran, Israel, Italy, Mexico, Portugal, Russia, Saudi Arabia, Spain, UK, 
USA, and Zimbabwe.
¶Diabetes educator; maternal–fetal medicine subspecialist; physician—general/family/primary care; critical care obstetrics.
HCP, healthcare professional.
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The mean change in SD from round 1 to 2 was −0.24 
(95% CI −0.27, −0.21). Forty- six outcomes met inclusion 
criteria by the end of round 2: among these, 22% related 
to behavior change and context, 17% to diet, 11% to 
glycemia and diabetes development, 7% to physical 
activity, and the remainder to a variety of other concepts 
(table 2). The 75 indeterminate outcomes were discussed 
and 8 were retained. Seven additional candidate outcomes 
arose from panel discussion, of which three were voted 
for inclusion (online supplemental material S1). The 57 
outcomes that met COS inclusion criteria were collapsed 
into 50 non- overlapping outcomes. For example, ‘carbo-
hydrate intake’, ‘fat intake’, ‘fiber intake’, ‘saturated fat 
intake’, and ‘total energy intake’ were collapsed into 
‘macronutrients’. The 50 outcomes were then classified 
by the panel into 19 domains: diabetes (n=3 outcomes), 
other related diseases (n=3), complications in subsequent 
pregnancy (n=2), offspring outcomes (n=3), adiposity 
(n=4), cardiometabolic measures (n=5), glycemia (n=3), 
physical activity (n=2), diet (n=4), breast feeding (n=2), 
behavior change theory (n=5), diabetes- related knowl-
edge (n=2), health literacy (n=1), social support (n=1), 
sleep (n=1), quality of life (n=1), program delivery (n=4), 
health economic evaluation (n=2), and diabetes risk 
screening (n=2) (figure 1).
The seven outcomes endorsed by ≥90% at round 2 
were type 2 diabetes development and GDM recurrence, 
attending the postpartum diabetes screening visit and 
completing oral glucose tolerance testing and/or other 
glycemia measures, weight and total energy intake, and 
health behaviors in general (online supplemental file 2).
The 15 at the 80%–90% endorsement level were 
knowledge related to diabetes and prevention behavior; 
perception of diabetes risk; and motivation to change; as 
well as completion of targets and activities of the program 
itself, and health service use and cost; and longer- term 
complications of diabetes like cardiovascular disease 
and more specific elements of the top 7, such as specific 
glycemia measures (OGTT, fasting glucose, and glycated 
hemoglobin); body mass index (BMI), which is comple-
mentary to weight; specific measures of health behaviors, 
such as sedentary time and moderate- to- vigorous phys-
ical activity; and dietary aspects other than total energy, 
including carbohydrate intake and dietary quality.
The consensus panel distinguished outcomes that were 
relevant, irrespective of time since delivery (13 domains 
and 34 outcomes) and outcomes pertinent to one of 
three specific time periods: weeks and months after 
delivery (four domains and eight outcomes), subsequent 
pregnancy (one domain and two outcomes), and later 
years (two domains and six outcomes) (figure 1).
DISCUSSION
The COS- DAP initiative engaged an international group 
of 115 stakeholders and 15 consensus panel members. 
The mean SD across outcome scores decreased between 
e- Delphi rounds, signaling overall convergence of 
opinion. The application of a priori criteria to the 
e- Delphi scores led to 50 outcomes. Importantly, these 
reflected not only disease development and physio-
logical effects but also patient- oriented outcomes like 
sleep quality and quality of life; health behaviors and 
behavioral theory constructs; knowledge, literacy, and 
risk perception; participation, adherence, and process 
outcomes; and economic measures. The relevance of 
some outcomes was a function of time since delivery 
or intervention focus. We believe that a comprehensive 
approach is crucial to facilitate the development and 
implementation of effective DAP programs.
Disease outcomes such as incident type 2 diabetes 
and cardiovascular disease were endorsed, as expected. 
Other disease outcomes included were recurrent GDM 
and gestational hypertension in a subsequent pregnancy, 
as well as type 1 diabetes; indeed, a subset of women 
with GDM develop type 1 diabetes rather than type 2 
diabetes in the years following pregnancy.15 Diabetes in 
the offspring was also endorsed; both type 2 diabetes and 
type 1 diabetes in offspring have been associated with 
GDM in the mother in previous studies.16 17
Our stakeholders endorsed quality of life and sleep 
quality, which are patient- oriented outcomes that are 
also related to diabetes risk. Lack of sleep and psychoso-
cial stress may increase risk of insulin resistance,18 19 and 
maternal sleep disordered breathing is associated with 
GDM development.20 Our COS is notable for focusing not 
only on biological effect measures but also on the behav-
iors that are expected to lead to these effects, namely, diet, 
physical activity, and breast feeding; these three domains 
captured outcomes such as sedentary time, macronutri-
ents, and breastfeeding length. Complementing these 
were the psychological factors (eg, perceived diabetes 
risk and motivation to change) that need to shift for 
behavioral change to occur. A systematic review of weight 
loss interventions determined that such factors were 
more strongly associated with program attrition than 
demographic factors.21 Some DAP prevention studies 
assess these factors at baseline,22 but their improvement 
over the course of an intervention may signal potential 
for behavioral and therefore metabolic change. Similarly, 
our stakeholders emphasized the importance of health 
literacy, diabetes knowledge, diabetes risk perception, 
and social support. Again, these may be not only baseline 
contextual factors but also factors that evolve during an 
intervention.
Our stakeholders also underscored program partici-
pation and program delivery outcomes. Previous DAP 
prevention studies have exhibited variation in both 
participation rates and their reporting23 24; this metric 
is crucial to justify the implementation of sustainable 
programs. Frameworks exist to encourage reporting of 
program delivery process measures,25 26 but COS- DAP 
represents a mandate to employ them. Finally, this COS 
recognizes the importance of collecting data to ascertain 
costs and cost effectiveness in order to achieve real- world 
implementation.
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Overall, a large number of outcomes met survey 
inclusion criteria, with round 2 scores ranging from 
69.9% to 98.3%. However, the diversity of outcomes 
is represented among even the top- scoring (ie, above 
84.5%) outcomes (online supplemental material S2). 
For example, although moderate- to- vigorous activity 
did not receive a score above 84.5%, sedentary time and 
health lifestyle behaviors did. Similarly, fiber and satu-
rated fat intake did not receive scores above 84.5%, but 
diet quality and carbohydrate intake scored highly. The 
ideal short- term study testing diabetes prevention inter-
ventions should thus consider impact on the breadth of 
outcomes in this COS, namely, disease outcomes, body 
weight/BMI, overall diet, physical activity, and comple-
tion of clinical tests. It should report on program- related 
process measures, such as the patient’s completion of 
targets/activities. Finally, the study should also consider 
some impact on patient knowledge and motivation, 
which are measures that may indicate impact beyond 
the study.
One main objective of the Delphi process is to be inclu-
sive of perspectives from a variety of stakeholders.12 It was 
thus important that we included three key stakeholder 
groups. HCPs did not endorse sleep quality highly, but 
researchers and women with GDM did, allowing this 
outcome to cross inclusion thresholds. Participation of 
women with GDM in the Delphi process was important 
in retaining ‘patient- oriented’ outcomes such as social 
support, quality of life, and dietary outcomes—their high 
endorsement of these outcomes in round one prompted 
HCPs and researchers to change their scores to similarly 
high numbers in round 2, or their high scoring of these 
outcomes pushed an otherwise lower total score past the 
inclusion threshold. In contrast, weight and adiposity 
measures were retained because of high endorsement by 
HCPs and researchers, but were not endorsed by women 
with GDM. Women’s low scores likely reflect the stigma of 
postpartum weight retention, which must be addressed 
so that inclusion of these important outcomes do not 
impact follow- up.
Our emphasis on inclusiveness of perspectives is also 
reflected by our application of a priori criteria following 
the e- Delphi survey. In contrast, as previously discussed, 
Bogdanet and colleagues developed a COS focusing 
on follow- up in women with medication- treated GDM, 
with an emphasis on brevity. During their consensus 
meeting, even outcomes with high endorsement during 
the e- Delphi process (≥70% of participants scoring 7–9) 
were considered for exclusion. A consensus panel is, by 
design, smaller and less diverse than a group of e- Delphi 
survey respondents. We argue that removing outcomes 
highly endorsed by the survey respondents gives the 
smaller consensus panel a disproportionate voice in 
determining what is core. Therefore, we emphasized 
fidelity to the e- Delphi process and comprehensive-
ness of the outcome set. This is important not only for 
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Strengths and limitations
COS- DAP gathered perspectives in three different languages 
from 23 countries. Most came from high- income and upper 
middle- income countries, which enhances the COS’ appli-
cability in these settings. However, it may be less applicable 
in low- income or middle- income countries. Of the women 
with GDM, most came from Canada and had previous 
experience participating in diabetes prevention studies.27 28 
Although not representative of the broader target popula-
tion, they had the background knowledge required to offer 
meaningful input.
Survey attrition was high, which aligns with reported 
higher attrition in surveys with greater than 50 items.29 Our 
attrition was primarily among women with GDM. A COS 
project for epilepsy in pregnancy also reported difficulty 
engaging patients in the Delphi process.30 As per ongoing 
discussions on COS methodology, patient input may be 
better captured with qualitative methods.11 Their input was 
nonetheless valuable, influencing the responses of other 
stakeholders during round 2 of the e- Delphi survey.
We quantified convergence of opinion in the Delphi 
process by examining the SD for each outcome’s scores. 
This approach is similar to Brookes and colleagues’ in their 
study of different Delphi feedback methods.31 COS devel-
opment guidelines emphasize methodological integrity if 
a project intends to combine perspectives from a heteroge-
nous group of participants.11 12 As previously mentioned, we 
were consistent with our published protocol and applied a 
priori survey criteria for outcome inclusion, only voting on 
indeterminate outcomes at the consensus meeting to avoid 
a COS biased toward the views of select individuals.
We acknowledge that the final COS captures a large 
number of outcomes, which may appear to increase 
participant burden. However, many are process measures 
and costs, captured through tracking during the inter-
vention. Some are relevant to only specific time periods 
relative to pregnancy. Therefore, adopting the COS 
may not be as difficult as the total number of outcomes 
may suggest. Further, there are key potential benefits—
they include identifying aspects of the strategy that may 
require optimization to enhance efficacy and deter-
mining whether implementation is feasible.
COS is subject to refinement as evidence evolves. Next 
steps may include engagement of women with GDM in 
a qualitative study to better discern their priorities, as 
well as a Consensus- based Standards for the Selection of 
Health Measurement Instruments initiative to identify 
how best to measure the outcomes in COS- DAP.
CONCLUSION
A growing body of health behavior change trials aim to 
prevent DAP in women at known high risk of diabetes. 
The COS- DAP initiative executed a methodologically 
rigorous process to define a COS that captures not only 
glycemia and cardiometabolic risk factors but also behav-
ioral, process, contextual, and economic measures. COS- 
DAP mandates that researchers consider a breadth of 
meaningful outcomes as core in this area of research. If 
research fails to consistently measure outcomes that are 
important to delivering impact on the health and well- 
being of this population, then the COS has failed to drive 
Figure 1 Core outcome set for diabetes after pregnancy prevention interventions. Fifty outcomes are grouped into 19 
domains and arranged according to when they are measured relative to time since pregnancy during the intervention. Health 
literacy, social support, and quality of life are individual outcomes. HDL, high- density lipoprotein; LDL, low- density lipoprotein.











are: first published as 10.1136/bm






9BMJ Open Diab Res Care 2020;8:e001594. doi:10.1136/bmjdrc-2020-001594
Epidemiology/Health services research
the change it states is at the center of its mandate. We call 
on the scientific community to apply COS- DAP in future 
trials to build a meaningful and actionable evidence base, 
and ultimately to improve health outcomes.
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S1. Additional outcomes voted for inclusion by consensus panel 
Outcome 
% of votes 
"in"* 
Rationale 
Indeterminate outcomes from the Delphi survey  
Dyslipidemia 71.4 
Risk factor for cardiovascular disease 
and prevalent in type 2 diabetics 
Gestational hypertension 78.6 
Risk factor for post-pregnancy 
cardiovascular disease 
Length of breastfeeding 100 
Increases insulin sensitivity and 
improves glucose metabolism in the 
mother 
Breastfeeding exclusivity 71.4 
Increases insulin sensitivity and 
improves glucose metabolism in the 
mother 
Infant birth weight and length for 
gestational age 
71.4 
Women with GDM are more likely to 
have macrosomic babies 
Diabetes in the offspring 71.4 
May indicate elevated risk of diabetes 
and CV disease in mother 
Health status for cost evaluation 78.6 
Cost evaluation will be important to 
implementation 
Study participation  71.4 
May help assess presence of 
barriers/enablers to completion of an 
intervention program 
Suggestions from consensus panel discussion 
Maternal hypertensive disease  78.6 
Includes diseases beyond gestational 
hypertension 
Infant hospitalization in neonatal care unit 85.7 
May indicate elevated risk of diabetes 
and CV disease in mother 
Sugary beverage intake 78.6 
Health behaviour associated with 
diabetes and CV disease 
*Number of voting members differed for outcomes of each origin: n=15 for indeterminate outcomes, 
n=14 for consensus panel suggestions  
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S2. Round 2 scores for outcomes that met inclusion criteria in the Delphi survey in 
descending order  
Outcome Percent of all participants rating 
outcome 7-9 
Gestational diabetes mellitus recurrence 98.3 
Diagnosis of type 2 diabetes 96.8 
Attending postpartum diabetes screening test 95.2 
Weight 94 
Total energy intake 93.1 
Healthy lifestyle behaviours 92.9 
Completion of OGTT/blood glucose/HbA1c post partum 92.1 
Diabetes knowledge 89.5 
Diabetes prevention behaviour knowledge 89.5 
Motivation to change 89.5 
Oral glucose tolerance test (OGTT) 89.3 
Fasting blood glucose 89.2 
Body mass index 88 
Diet quality 87.9 
Completion of targets/activities 87.5 
Perceived diabetes risk 86 
Glycated hemoglobin test 84.5 
Carbohydrate intake 84.5 
Sedentary time 84.5 
Cardiovascular disease 82.5 
Health service utilisation and cost 82.2 
Moderate to vigorous activity 81.1 
Fat intake 79.3 
Post-partum weight retention 79.1 
Social support 79 
Diagnosis of type 1 diabetes 77.8 
Saturated fat intake 77.7 
Intervention components engaged with 76.7 
Quality of Life 76.2 
Fibre intake 75.9 
Diet self-efficacy 75.4 
Neonatal mortality/stillbirth 75.1 
Diastolic blood pressure 74.6 
LDL cholesterol 74.6 
Perceived barriers 73.7 
Whether goals were set for the woman and achieved 73.1 
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Food group servings 72.4 
Glycaemic load 72.4 
Health literacy 72 
Weight self-efficacy 72 
Waist circumference 71.7 
Hypertension 71.4 
Systolic blood pressure 71.4 
Intensity of exercise 70.6 
Sleep quality 70.6 
HDL cholesterol 69.9 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Diab Res Care
 doi: 10.1136/bmjdrc-2020-001594:e001594. 8 2020;BMJ Open Diab Res Care, et al. Wu N
